title: The effects of platelet-activating factor on flow rate and eicosanoid release in the isolated perfused rat gastric vascular bed.
abstract: In the isolated rat stomach perfused via the vasculature in situ under constant pressure bolus injections of platelet-activating factor (PAF, 3, 16, or 50 ng) induced dose-dependent, long-lasting reductions of flow rates and simultaneously significant increases in the release of cysteinyl-leukotrienes (cys-LT), thromboxane (TX) B2 and 6-keto-prostaglandin (PG) F1 alpha. Reversed phase high pressure liquid chromatography demonstrated the release of a mixture of comparable amounts of LTC4, LTD4 and LTE4 by PAF. Inhibition of cys-LT synthesis by the lipoxygenase inhibitors nordihydroguaiaretic acid (NDGA) and L-651,896 did not significantly affect PAF-induced flow reduction indicating that endogenous cys-LT are of minor importance for the PAF effect on gastric vascular flow. This conclusion is supported by the fact that the cys-LT receptor antagonist FPL 55712 in a concentration (1 x 10(-6) M) that completely antagonized gastric flow reduction by exogenous LTC4 (1 x 10(-7) M) had no effect on the PAF-induced reduction of flow. The cyclooxygenase inhibitor indomethacin aggravated the PAF-induced flow reduction suggesting that the endogenous vasodilator PGI2 might act as a functional PAF antagonist in the rat gastric vascular bed. In contrast to FPL 55712 the PAF antagonist BN 52021 significantly and concentration-dependently antagonized the PAF effect on gastric vascular flow. The results demonstrate that PAF and LTC4 induce flow reductions in the rat gastric vascular bed by activating different receptors and that endogenous eicosanoids released by PAF do not contribute significantly to the PAF effect on gastric vascular flow.
authors.affiliation: Dept. of Experimental and Clinical Medicine, Ruhr-Univ. of Bochum, FRG.
authors.forename: A
authors.initials: A
authors.lastname: Dembinska-Kiec
authors.forename: B A
authors.initials: BA
authors.lastname: Peskar
authors.forename: M K
authors.initials: MK
authors.lastname: Muller
authors.forename: B M
authors.initials: BM
authors.lastname: Peskar
mesh_terms: D015121:6-Ketoprostaglandin F1 alpha / Q000378:metabolism*; D000818:Animals; D001572:Benzofurans / Q000494:pharmacology; D001783:Blood Flow Velocity; D002851:Chromatography, High Pressure Liquid; D002867:Chromones / Q000494:pharmacology; D004224:Diterpenes; D005753:Gastric Mucosa / Q000378:metabolism; D046934:Ginkgolides; D007213:Indomethacin / Q000494:pharmacology; D007783:Lactones / Q000494:pharmacology; D016859:Lipoxygenase Inhibitors; D008297:Male; D009637:Masoprocol / Q000494:pharmacology; D010972:Platelet Activating Factor / Q000037:antagonists & inhibitors / Q000494:pharmacology*; D051381:Rats; D011919:Rats, Inbred Strains; D013189:SRS-A / Q000037:antagonists & inhibitors / Q000378:metabolism*; D013270:Stomach / Q000098:blood supply*; D013929:Thromboxane B2 / Q000378:metabolism*
chemical_list: D001572:Benzofurans; D002867:Chromones; D004224:Diterpenes; D046934:Ginkgolides; D007783:Lactones; D016859:Lipoxygenase Inhibitors; D010972:Platelet Activating Factor; D013189:SRS-A; D013929:Thromboxane B2; D015121:6-Ketoprostaglandin F1 alpha; D009637:Masoprocol; C006312:FPL 55712; C053727:L 651896; C045856:ginkgolide B; D007213:Indomethacin